# Ashvattha Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ashvattha-therapeutics

- Industry: Biotechnology
- Headquarters: Redwood City, US
- Website: www.avttx.com
- Total disclosed funding: $119M
- Latest round: Series B (Jan 13, 2025)
- Investors on record: 5

## About

Founded in 2015 and based in California, US, Ashvattha Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for the treatment of various diseases. In January 2025, Ashvattha Therapeutics, Inc. raised USD 50 million in venture funding co-led by returning investors Tribe Capital and Natural Capital.

Ashvattha Therapeutics, Inc. utilizes a proprietary Hydroxyl Dendrimer (HD) platform to produce novel HD therapeutics (hydroxyl dendrimer therapeutics) that selectively target the inflamed tissues or diseased cells in the human body. The company’s precision medicines can be used for the treatment of various therapeutical areas including neurology, ophthalmology, hyperinflammatory, and neuro-oncology. The firm’s product pipeline comprises OP-101, D-4517.2, OP-801, and D6-B483.

The company will use the April 2022 funding for the advancement of its pipeline of hydroxyl dendrimer therapeutics (HDTs), including other multiple clinical-stage programs.

## Funding rounds

- Series B, Jan 13, 2025, $50M — Natural Capital, Tribe Capital
- Series B, Apr 27, 2022, $69M — Plum Alley, Natural Capital, Tribe Capital, Huadong Medicine
- Series A, May 17, 2019, $0.3M — EcoR1 Capital, Natural Capital

## Investors

- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series A
- Natural Capital — Series A, Series B
- Plum Alley (https://capitalatlas.ai/funds/plum-alley) — Series B
- Tribe Capital (https://capitalatlas.ai/funds/tribe-capital) — Series B
- Huadong Medicine — Series B